Individual immunodominant CD8+ T cell clones monitoring in patients with metastatic melanoma.

We investigated the presence of individual melanoma-specific T cell clones in patients with metastatic melanoma. Ten patients were examined for the presence of melanoma-reactive T cells using dendritic cells loaded with autologous tumor cells. Their specificity was tested using non-radiactive cytotoxicity test. Individual immunodominant T cell clones were identified by the clonotypic assay that combines in vitro cell culture, immunomagnetic sorting of activated IFNg+ T cells, T cell receptor beta locus anchored reverse transcription-PCR, and clonotypic quantitative PCR.
All patients had detectable melanoma-reactive T cells in vitro. Expanded melanoma-reactive T cells demonstrated specific cytotoxic effect against autologous tumor cells in vitro. Three patients experienced objective responses and their clinical responses were closely associated with the in vivo expansion and long-term persistence of individual CD8+ T cell clones with frequencies of 10–6 to 10–3 of all circulating CD8+ T cells. Five patients with progressive disease experienced no or temporary presence of circulating melanoma-reactive T cell clones. Thus, circulating immunodominant CD8+ T cell clones closely correlate with clinical outcome in patients with metastatic melanoma.

Supported by MŠMT NPVII 2B06058.